BioSapien is building partnership pathways around clinical validation, platform expansion.
Pharmaceutical Companies
We partner with pharma to unlock assets limited by systemic toxicity or poor tumor penetration. MediChip™ reformulates existing and pipeline compounds into a biodegradable, 3D-printed implant that delivers drug directly at the disease site. Partnerships span co-development, reformulation of approved products, and platform licensing — extending asset lifecycle and opening indications that systemic dosing can't reach.
.webp)
Academic Research Centers
We collaborate with leading research institutions to advance the science behind localized delivery. Partners gain access to the MediChip™ platform for preclinical and translational studies, with joint programs spanning formulation, manufacturing, and mechanism of action. Our work with academic centers has produced GMP manufacturing capability, shared research infrastructure, and co-developed data supporting our clinical programs.
.webp)
Clinical Investigators
We work directly with investigators to design and run trials that answer real clinical questions. Our teams support protocol development, site activation, and regulatory strategy across US and international sites. Investigators help shape indication selection and study design from the outset — bringing frontline surgical and oncology insight to a platform built to be placed at the tumor bed.
.webp)
Government & Healthcare Organizations
We partner with health authorities and national healthcare systems to build the infrastructure advanced therapies require. BioSapien conducted the first pre-IND meeting between a biotech and the UAE Department of Health, structured to FDA standards, and works with government partners on regulatory pathway design, local manufacturing, and clinical trial capacity — bringing novel treatments to patients within their own health systems.
Help shape the future of localizedcancer therapy.
Whether you're a pharmaceutical company, research institution, clinical investigator, or strategic partner, we're building the next generation of localized oncology treatments together.
.avif)